Atlas Trials

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

Clinical trial NCT05605613 · UNKNOWN

Trial details

NCT number
NCT05605613
Sponsor
Xuhua Duan
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
NSCLC
Start date
2022-10-29
Primary completion
2023-11-15
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.